SK Biopharmaceuticals Co., Ltd. (326030.KS)
KRW 103600.0
(-2.54%)
KRW 103600.0
(-2.54%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -22.2 Billion KRW | 80.37% |
| 2022 | -125.76 Billion KRW | -231.7% |
| 2021 | 106.6 Billion KRW | 137.91% |
| 2020 | -224.58 Billion KRW | -206.2% |
| 2019 | -73.98 Billion KRW | 44.72% |
| 2018 | -134.26 Billion KRW | -43.04% |
| 2017 | -95.76 Billion KRW | -256.6% |
| 2016 | -54.58 Billion KRW | 16.87% |
| 2015 | -31.56 Billion KRW | -1.41% |
| 2014 | -31.89 Billion KRW | 16.83% |
| 2013 | -38.9 Billion KRW | -65.96% |
| 2012 | -24.19 Billion KRW | -103.86% |
| 2011 | -15.29 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 30.37 Billion KRW | 107.13% |
| 2024 Q1 | 14.62 Billion KRW | -23.92% |
| 2023 Q1 | 6.09 Billion KRW | 113.58% |
| 2023 Q3 | 83.54 Billion KRW | 23.51% |
| 2023 Q2 | 67.63 Billion KRW | 1009.09% |
| 2023 FY | - KRW | 80.37% |
| 2023 Q4 | 19.27 Billion KRW | -76.93% |
| 2022 FY | - KRW | -231.7% |
| 2022 Q4 | -44.89 Billion KRW | -557.04% |
| 2022 Q3 | -6.83 Billion KRW | 79.74% |
| 2022 Q2 | -33.72 Billion KRW | -21.93% |
| 2022 Q1 | -27.66 Billion KRW | -151.67% |
| 2021 FY | - KRW | 137.91% |
| 2021 Q4 | 53.52 Billion KRW | 243.57% |
| 2021 Q2 | -62.81 Billion KRW | -147.42% |
| 2021 Q3 | -37.28 Billion KRW | 40.65% |
| 2021 Q1 | 132.45 Billion KRW | 366.91% |
| 2020 FY | - KRW | -206.2% |
| 2020 Q4 | -49.62 Billion KRW | 15.73% |
| 2020 Q2 | -55.02 Billion KRW | 12.64% |
| 2020 Q1 | -62.98 Billion KRW | 0.41% |
| 2020 Q3 | -58.89 Billion KRW | -7.03% |
| 2019 Q4 | -63.24 Billion KRW | -31.3% |
| 2019 FY | - KRW | 44.72% |
| 2019 Q3 | -48.17 Billion KRW | -26.97% |
| 2019 Q2 | -37.94 Billion KRW | -150.0% |
| 2019 Q1 | 75.87 Billion KRW | 0.0% |
| 2018 FY | - KRW | -43.04% |
| 2017 FY | - KRW | -256.6% |
| 2016 FY | - KRW | 16.87% |
| 2015 FY | - KRW | -1.41% |
| 2014 FY | - KRW | 16.83% |
| 2013 FY | - KRW | -65.96% |
| 2012 FY | - KRW | -103.86% |
| 2011 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ORIENT BIO Inc. | 15.66 Billion KRW | 241.729% |
| Green Cross Holdings Corporation | 66.84 Billion KRW | 133.22% |
| Green Cross Holdings Corporation | 109.81 Billion KRW | 120.221% |
| Pharmicell Co., Ltd. | 8.44 Billion KRW | 363.079% |
| Green Cross Corporation | 109.81 Billion KRW | 120.221% |
| GeneOne Life Science, Inc. | -63.69 Billion KRW | 65.141% |
| Celltrion, Inc. | 897.26 Billion KRW | 102.475% |
| Samsung Biologics Co.,Ltd. | 1603.46 Billion KRW | 101.385% |
| SK bioscience Co.,Ltd. | 22.77 Billion KRW | 197.488% |
| Prestige BioPharma Limited | -31.04 Billion KRW | 28.481% |